NCT01510171View on ClinicalTrials.gov

Rapid Activity of Platelet Inhibitor Drugs Study

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2013

Conditions
ST-segment Elevation Myocardial Infarction
Interventions
DRUG

Prasugrel

25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.

DRUG

Ticagrelor

25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.

Trial Locations (1)

50134

Careggi Hospital, Florence

All Listed Sponsors
lead

Careggi Hospital

OTHER

NCT01510171 - Rapid Activity of Platelet Inhibitor Drugs Study | Biotech Hunter | Biotech Hunter